Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.56 |
| ▸ | PGR | P06401 | 1/20 | 0.56 |
| ▸ | AR | P10275 | 1/20 | 0.56 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.56 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | MMP1 | P03956 | 1/20 | 0.55 |
| ▸ | MMP2 | P08253 | 1/20 | 0.55 |
| ▸ | MMP9 | P14780 | 1/20 | 0.55 |
| ▸ | MMP8 | P22894 | 1/20 | 0.55 |
| ▸ | MMP13 | P45452 | 1/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.54 |
| ▸ | CDK1 | P06493 | 1/20 | 0.54 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.54 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.54 |
| ▸ | CDK2 | P24941 | 1/20 | 0.54 |
| ▸ | CDK7 | P50613 | 1/20 | 0.54 |
| ▸ | CCNH | P51946 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5046801 | 0.85 | FFAR1 (0.51) | ARCA1CA2FFAR1CDK1 | |
| SCHEMBL5037026 | 0.85 | NR3C1 (0.64) | TSHRNR3C1PGRARESR2 | |
| SCHEMBL3762909 | 0.83 | PGR (0.77) | TSHRNR3C1PGRARESR2 | |
| SCHEMBL3430931 | 0.82 | PGR (0.53) | PGRKMT2AHDAC1HDAC8LMNA | |
| SCHEMBL5047109 | 0.79 | KMT2A (0.58) | PGRKMT2AGAAHDAC1HDAC8 | |
| SCHEMBL5042029 | 0.79 | PGR (0.53) | PGRHSD17B2KMT2AHDAC8MEN1 | |
| SCHEMBL9811664 | 0.79 | POLB (0.68) | PGRCA1CA2KMT2AMEN1 | |
| SCHEMBL5040194 | 0.79 | PGR (0.68) | TSHRPGRLMNAMAPTALDH1A1 | |
| SCHEMBL19065106 | 0.78 | TSHR (0.64) | TSHRNR3C1PGRARESR2 | |
| SCHEMBL965226 | 0.78 | KEAP1 (0.66) | PGRCA1CA2KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1250325-B1 | PHENANTHRIDINE-N-OXIDES | NYCOMED GMBH (DE) | 2008-05-07 | — | — | EP | disclosed |
| US-6630483-B2 | Phenanthridine-N-oxides | ALTANA PHARMA AG (DE) | 2003-10-07 | — | — | US | disclosed |
| US-20030105123-A1 | For therapy of respiratory system disorders | ALTANA PHARMA AG (DE) | 2003-06-05 | — | — | US | disclosed |
| EP-1250325-A1 | PHENANTHRIDINE-N-OXIDES | ALTANA Pharma AG (DE) | 2002-10-23 | — | — | EP | disclosed |
| EP-0889886-B1 | NOVEL PHENANTHRIDINES SUBSTITUTED IN THE 6 POSITION | ALTANA PHARMA AG (DE) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001051470-A1 | PHENANTHRIDINE-N-OXIDES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2001-07-19 | — | — | WO | disclosed |
| US-6127378-A | A PHOSPHODIESTERASE ENZYME INHIBITOR AS BRONCHIAL THERAPEUTICS, AN ANTIINFLAMMATORY AGENT TREATING ASTHMA PROPHYLAXIS, SKIN DISORDERS, INTESTINE DISORDERS, EYE DISORDERS, CENTRAL NERVOUS SYSTEM DISORDERS, JOINTS DISORDERS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-10-03 | — | — | US | disclosed |
| EP-0889886-A1 | NOVEL PHENANTHRIDINES SUBSTITUTED IN THE 6 POSITION | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1999-01-13 | — | — | EP | disclosed |
| WO-1997035854-A1 | NOVEL PHENANTHRIDINES SUBSTITUTED IN THE 6 POSITION | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1997-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105123-A1 | For therapy of respiratory system disorders | CHRM3, CYP11B1, CYP11B2 | TSHR 183/4885NR3C1 15/4885PGR 1707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.